Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions.
Annika AndersonWilliam RowlesShane PooleAyushi BalanCarolyn BevanRachel BrandstadterAndrea I CipleaJoanna CooperMichelle FabianThomas W HaleDina JacobsMihir KakaraKristen M KryskoErin E LongbrakeJacqueline MarcusPavle RepovicClaire S RileyAndrew R RomeoAlice RutatangwaTimothy WestKerstin HellwigSara C LaHueRiley BovePublished in: Annals of clinical and translational neurology (2023)
These confirm minimal transfer of mAb into breastmilk. Anti-CD20 mAb therapy stabilizes MS activity before conception to the postpartum period, and postpartum treatments appears to be safe and well-tolerated for both mother and infant.